Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Quarterly Earnings Results

Y-mAbs Therapeutics (NASDAQ:YMAB) issued its quarterly earnings results on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10, Zacks reports. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $3.64 on Thursday. The business has a 50 day moving average price of $4.50 and a 200 day moving average price of $7.26. The company has a market capitalization of $164.81 million, a P/E ratio of -6.74 and a beta of 0.53. Y-mAbs Therapeutics has a 1-year low of $3.63 and a 1-year high of $16.11.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on YMAB. HC Wainwright reduced their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Bank of America lowered Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a report on Tuesday, April 22nd. Truist Financial reduced their price target on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday. Morgan Stanley reduced their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. Finally, Oppenheimer lowered their price target on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.70.

Insider Activity

In other news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This trade represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 22.50% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.